ENGLEWOOD, Colo., Oct. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex as 23rd in the Top 100 Healthcare Technology Companies of 2023. 2023 is the second year Zynex has been included within the report's top 100. Last year, Zynex ranked as the 33rd company.
"We're pleased to be included in the Top 100 Healthcare Technology Companies of 2023 list for the second year in a row," said Thomas Sandgaard, CEO of Zynex. "As in years past, the list represents a wide portfolio of products and solutions. We are humbled to know that Zynex's emphasis on non-invasive patient solutions is being recognized within the life sciences community and beyond."
About The Healthcare Technology Report
The Healthcare Technology Report (HLTR) provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$1.67 |
Daily Change: | 0.01 0.60 |
Daily Volume: | 17,756 |
Market Cap: | US$50.600M |
August 18, 2025 July 31, 2025 June 30, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load